Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2004

View Archived Issues

Simultaneous targeting of tumor proliferation and angiogenesis shows promising results in vivo

Erbitux in phase III for NSCLC

Interim results of BrachySil phase IIa study in liver cancer patients

Yondelis receives orphan drug status for soft tissue sarcoma

Peninsula completes phase I study for PPI-0903

Cand5 enters phase I study for AMD

BDC-03 under development for cachexia

Positive phase II results for cetrorelix in BPH

Diamyd studied in type 2 diabetes patients in Sweden

Phase III Inactine acute study cleared to continue

Celltech researchers claim anti-IL-1beta antibodies and their use

Novel gastric antisecretory agents discovered at Altana

New NO-releasing COX inhibitors in early development at Altana

New MIF inhibitors prepared and tested at Avanir

AstraZeneca team presents new P2X7 antagonists

Aventis scientists design inhibitors of fungal CIV1 and other kinases

Three novel series of pyridine-based immunosuppressants developed at AstraZeneca

No FDA approval for Exanta

Norditropin NordiFlex receives FDA approval

In vivo tumor growth inhibition and apoptosis induced by human agonistic TRAIL receptor 2 antibody

Novel prophylactic and therapeutic HPV vaccine approach

Antibody therapy promising against C. difficile

Progress in development and testing of recombinant hookworm vaccine

Orally active cathepsin K inhibitor prevents bone loss in vitro and in vivo

ArTec prepares to review preclinical application for Tubercin with FDA

Allergan and Peplin discontinue PEP-005 collaboration

Neoprobe updates RIGScan CR and Lymphoseek programs

Initiation of MERLIN TIMI-36 study of Ranexa

Provecta IND cleared

Nabi begins a new clinical trial with PhosLo in ESRD

Ursodeoxycholate boosts chemoprotective efficacy of sulindac

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...